Using AI to design better drugs by understanding how they work
From atoms to mechanisms - Artificial Intelligence augmented molecular simulations for mechanistic ligand design
This study is exploring how artificial intelligence can help create better medications by understanding how drugs interact with their targets over time, which could lead to more effective treatments for patients with diseases related to specific proteins.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project ID | NIH-10915566 on NIH RePORTER |
What this research studies
This research focuses on improving drug design by utilizing artificial intelligence to simulate and understand the dynamic behavior of drug targets. It aims to develop new computational methods that can accurately model how drugs interact with their targets over time, rather than relying on static models. By integrating AI with molecular dynamics simulations, the research seeks to identify effective inhibitors for specific proteins, such as tyrosine kinases, which are crucial in various diseases. Patients may benefit from more effective and targeted medications developed through these advanced methodologies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that involve tyrosine kinases or similar drug targets.
Not a fit: Patients with conditions unrelated to the mechanisms being studied, or those who do not respond to kinase inhibitors, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and targeted drugs for patients.
How similar studies have performed: Other research has shown promise in using AI for drug design, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
College Park, United States
- Univ of Maryland, College Park — College Park, United States (Active)
Researchers
- Principal investigator: Tiwary, Pratyush — Univ of Maryland, College Park
- Study coordinator: Tiwary, Pratyush
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.